Literature DB >> 27717791

Patient preferences for inflammatory bowel disease treatment objectives.

Francesc Casellas1, Claudia Herrera-de Guise2, Virginia Robles2, Ester Navarro2, Natalia Borruel2.   

Abstract

BACKGROUND: There is currently little evidence about what treatment objectives most interest patients with inflammatory bowel disease (IBD). AIMS: To determine patient preferences regarding IBD treatment objectives, specially the attributes they value most and the symptoms to be controlled as a priority.
METHODS: Prospective, observational, anonymous study conducted in 117 outpatients with Crohn's disease or ulcerative colitis.
RESULTS: The most important treatment objectives from the patients' perspective were: improving quality of life (40.2% of patients), and completely resolving symptoms (33.3%). Only 12.8% of patients indicated having a completely normal colonoscopy as a preferred objective. The symptoms the patients considered to be most important when prioritizing their control were: abdominal pain (23.1% of patients), and bowel movement urgency (17.1%). The preferred treatment objectives were similar for Crohn's disease and ulcerative colitis patients.
CONCLUSIONS: Improving quality of life and completely controlling symptoms are the priority treatment objectives for IBD patients, with abdominal pain being the most important symptom. Conversely, therapeutic objective target goals proposed by physicians, such as healing the mucosal lesions, are not a priority for most patients. This indicates that there are discrepancies between patient and physician expectations, which should be taken into account if a patient-centered care model is to be implemented.
Copyright © 2016 Editrice Gastroenterologica Italiana S.r.l. Published by Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Crohn’s disease; Symptoms; Treatment expectations; Ulcerative colitis

Mesh:

Year:  2016        PMID: 27717791     DOI: 10.1016/j.dld.2016.09.009

Source DB:  PubMed          Journal:  Dig Liver Dis        ISSN: 1590-8658            Impact factor:   4.088


  13 in total

Review 1.  Factors that Influence Treatment and Non-treatment Decision Making Among Individuals with Inflammatory Bowel Disease: An Integrative Review.

Authors:  Kendra J Kamp; Kelly Brittain
Journal:  Patient       Date:  2018-06       Impact factor: 3.883

Review 2.  AGA Technical Review on the Management of Mild-to-Moderate Ulcerative Colitis.

Authors:  Siddharth Singh; Joseph D Feuerstein; David G Binion; William J Tremaine
Journal:  Gastroenterology       Date:  2018-12-18       Impact factor: 22.682

Review 3.  AGA Clinical Practice Guidelines on the Management of Mild-to-Moderate Ulcerative Colitis.

Authors:  Cynthia W Ko; Siddharth Singh; Joseph D Feuerstein; Corinna Falck-Ytter; Yngve Falck-Ytter; Raymond K Cross
Journal:  Gastroenterology       Date:  2018-12-18       Impact factor: 22.682

Review 4.  Inflammatory bowel disease (IBD) position statement of the Italian Society of Colorectal Surgery (SICCR): general principles of IBD management.

Authors:  G Pellino; D S Keller; G M Sampietro; V Annese; M Carvello; V Celentano; C Coco; F Colombo; N Cracco; F Di Candido; M Franceschi; S Laureti; G Mattioli; L Pio; G Sciaudone; G Sica; V Villanacci; R Zinicola; S Leone; S Danese; A Spinelli; G Delaini; F Selvaggi
Journal:  Tech Coloproctol       Date:  2020-01-25       Impact factor: 3.781

5.  Canadian Association of Gastroenterology Clinical Practice Guideline for the Management of Luminal Crohn's Disease.

Authors:  Remo Panaccione; A Hillary Steinhart; Brian Bressler; Reena Khanna; John K Marshall; Laura Targownik; Waqqas Afif; Alain Bitton; Mark Borgaonkar; Usha Chauhan; Brendan Halloran; Jennifer Jones; Erin Kennedy; Grigorios I Leontiadis; Edward V Loftus; Jonathan Meddings; Paul Moayyedi; Sanjay Murthy; Sophie Plamondon; Greg Rosenfeld; David Schwartz; Cynthia H Seow; Chadwick Williams; Charles N Bernstein
Journal:  J Can Assoc Gastroenterol       Date:  2018-07-10

Review 6.  AGA Technical Review on the Medical Management of Moderate to Severe Luminal and Perianal Fistulizing Crohn's Disease.

Authors:  Siddharth Singh; Deborah Proctor; Frank I Scott; Yngve Falck-Ytter; Joseph D Feuerstein
Journal:  Gastroenterology       Date:  2021-06       Impact factor: 33.883

7.  Patients' perceptions of the impact of ulcerative colitis on social and professional life: results from the UC-LIFE survey of outpatient clinics in Spain.

Authors:  Xavier Calvet; Federico Argüelles-Arias; Antonio López-Sanromán; Luis Cea-Calvo; Berta Juliá; Cristina Romero de Santos; Daniel Carpio
Journal:  Patient Prefer Adherence       Date:  2018-09-18       Impact factor: 2.711

8.  A Qualitative Research for Defining Meaningful Attributes for the Treatment of Inflammatory Bowel Disease from the Patient Perspective.

Authors:  Edouard Louis; Juan M Ramos-Goñi; Jesus Cuervo; Uri Kopylov; Manuel Barreiro-de Acosta; Sara McCartney; Greg Rosenfeld; Dominik Bettenworth; Ailsa Hart; Kerri Novak; Xavier Donnet; David Easton; Roberto Saldaña; Katja Protze; Eyal Tzur; Gabriela Alperovich; Francesc Casellas
Journal:  Patient       Date:  2020-06       Impact factor: 3.883

9.  Patient preferences for maintenance therapy in Crohn's disease: A discrete-choice experiment.

Authors:  Glen S Hazlewood; Gyanendra Pokharel; Robert Deardon; Deborah A Marshall; Claire Bombardier; George Tomlinson; Christopher Ma; Cynthia H Seow; Remo Panaccione; Gilaad G Kaplan
Journal:  PLoS One       Date:  2020-01-16       Impact factor: 3.240

10.  Cognitive-behavioural therapy for the management of inflammatory bowel disease-fatigue: a feasibility randomised controlled trial.

Authors:  Micol Artom; Wladyslawa Czuber-Dochan; Jackie Sturt; Hannah Proudfoot; Danniella Roberts; Christine Norton
Journal:  Pilot Feasibility Stud       Date:  2019-12-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.